{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:21:16Z","timestamp":1768634476442,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) constitutes an independent risk factor for the development of coronary heart disease. Low-grade inflammation has been shown to play an important role in the development of atherosclerosis and NAFLD. Free fatty acid receptor 4 (FFAR4\/GPR120), which is involved in damping inflammatory reactions, may represent a promising target for the treatment of inflammatory diseases. Our objective was to evaluate the effect of TUG-891, the synthetic agonist of FFAR4\/GPR120, on fatty liver in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The effect of TUG-891 on fatty liver was investigated in apoE<jats:sup>\u2212\/\u2212<\/jats:sup> mice fed a high-fat diet (HFD), using microscopic, biochemical, molecular, and proteomic methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment with TUG-891 inhibited the progression of liver steatosis in apoE<jats:sup>\u2212\/\u2212<\/jats:sup> mice, as evidenced by histological analysis, and reduced the accumulation of TG in the liver. This action was associated with a decrease in plasma AST levels. TUG-891 decreased the expression of liver genes and proteins involved in de novo lipogenesis (Srebp-1c, Fasn and Scd1) and decreased the expression of genes related to oxidation and uptake (Acox1, Ehhadh, Cd36, Fabp1). Furthermore, TUG-891 modified the levels of selected factors related to glucose metabolism (decreased\u00a0Glut2, Pdk4 and Pklr, and increased\u00a0G6pdx).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pharmacological stimulation of FFAR4 may represent a promising lead in the search for drugs that inhibit NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s10557-023-07430-7","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:03:07Z","timestamp":1674806587000},"page":"667-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice"],"prefix":"10.1007","volume":"38","author":[{"given":"Anna","family":"Kiepura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Suski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Stachyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Ku\u015b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Czepiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wi\u015bniewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Ulatowska-Bia\u0142as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-3732","authenticated-orcid":false,"given":"Rafa\u0142","family":"Olszanecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"7430_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/biomedicines9050467","volume":"9","author":"A Kiepura","year":"2021","unstructured":"Kiepura A, Stachyra K, Olszanecki R. Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4). Biomedicines. 2021;9:467.","journal-title":"Biomedicines"},{"issue":"7","key":"7430_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337.","journal-title":"Clin Res Cardiol"},{"key":"7430_CR3","doi-asserted-by":"publisher","first-page":"10688","DOI":"10.3390\/ijms221910688","volume":"22","author":"A Wi\u015bniewska","year":"2021","unstructured":"Wi\u015bniewska A, Stachowicz A, Ku\u015b K, et al. Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride\/High-Density Lipoprotein Cholesterol Ratio. Int J Mol Sci. 2021;22:10688.","journal-title":"Int J Mol Sci"},{"key":"7430_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.","journal-title":"Diabetol Metab Syndr"},{"key":"7430_CR5","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.3390\/ijms22189772","volume":"22","author":"A Kiepura","year":"2021","unstructured":"Kiepura A, Stachyra K, Wi\u015bniewska A, et al. The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE-Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype. Int J Mol Sci. 2021;22:9772.","journal-title":"Int J Mol Sci"},{"key":"7430_CR6","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u201327.","journal-title":"Cell Mol Life Sci"},{"key":"7430_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","volume":"38","author":"MC Petersen","year":"2017","unstructured":"Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci. 2017;38:649\u201365.","journal-title":"Trends Pharmacol Sci"},{"key":"7430_CR8","first-page":"171","volume":"100","author":"I Kimura","year":"2019","unstructured":"Kimura I, Ichimura A, Ohue-Kitano R, et al. Free Fatty Acid Receptors in Health and Disease. Physiol Rev Am Physiol Soc. 2019;100:171\u2013210.","journal-title":"Physiol Rev Am Physiol Soc"},{"key":"7430_CR9","doi-asserted-by":"publisher","first-page":"104604","DOI":"10.1016\/j.phrs.2019.104604","volume":"152","author":"A Bartoszek","year":"2020","unstructured":"Bartoszek A, Moo EV, Binienda A, et al. Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases. Pharmacol Res. 2020;152:104604.","journal-title":"Pharmacol Res"},{"key":"7430_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ecl.2008.06.007","volume":"37","author":"G Boden","year":"2008","unstructured":"Boden G. Obesity and Free Fatty Acids (FFA). Endocrinol Metab Clin N Am. 2008;37:635\u2013ix.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"5","key":"7430_CR11","first-page":"236","volume":"6","author":"A Ichimura","year":"2014","unstructured":"Ichimura A, Hasegawa S, Kasubuchi M, et al. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol. 2014;6(5):236.","journal-title":"Front Pharmacol"},{"key":"7430_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature10798","volume":"483","author":"A Ichimura","year":"2012","unstructured":"Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012;483:350\u20134.","journal-title":"Nature"},{"key":"7430_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","volume":"142","author":"DY Oh","year":"2010","unstructured":"Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin Sensitizing Effects. Cell. 2010;142:687\u201398.","journal-title":"Cell"},{"key":"7430_CR14","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.1038\/srep12931","volume":"5","author":"R Schierwagen","year":"2015","unstructured":"Schierwagen R, Mayb\u00fcchen L, Zimmer S, et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep. 2015;5:12931.","journal-title":"Sci Rep"},{"key":"7430_CR15","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707\u201318.","journal-title":"Drug Discov Today"},{"key":"7430_CR16","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1007\/s10620-007-9740-5","volume":"52","author":"MD Demirag","year":"2007","unstructured":"Demirag MD, Onen HI, Karaoguz MY, et al. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52:3399\u2013403.","journal-title":"Dig Dis Sci"},{"key":"7430_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1411543","volume":"258","author":"SH Zhang","year":"1992","unstructured":"Zhang SH, Reddick RL, Piedrahita JA, et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468\u201371.","journal-title":"Science"},{"key":"7430_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbrc.2014.06.060","volume":"450","author":"Y Wang","year":"2014","unstructured":"Wang Y, Lu H, Huang Z, et al. Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta. Biochem Biophys Res Commun. 2014;450:788\u201393.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"7430_CR19","doi-asserted-by":"publisher","first-page":"e8047","DOI":"10.15252\/emmm.201708047","volume":"10","author":"M Schilperoort","year":"2018","unstructured":"Schilperoort M, van Dam AD, Hoeke G, et al. The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat. EMBO Mol Med. 2018;10(3):e8047.","journal-title":"EMBO Mol Med"},{"issue":"40","key":"7430_CR20","first-page":"1143","volume":"2016","author":"D Gozal","year":"2005","unstructured":"Gozal D, Qiao Z, Almendros I, et al. Treatment with TUG891, a free fatty acid receptor 4 agonist, restores adipose tissue metabolic dysfunction following chronic sleep fragmentation in mice. Int J Obes. 2005;2016(40):1143\u20139.","journal-title":"Int J Obes"},{"key":"7430_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.pharep.2019.02.014","volume":"71","author":"M Suski","year":"2019","unstructured":"Suski M, Kiepura A, Wi\u015bniewska A, et al. Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice. Pharmacol Rep PR. 2019;71:551\u20135.","journal-title":"Pharmacol Rep PR"},{"key":"7430_CR22","doi-asserted-by":"publisher","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9:e115922.","journal-title":"PLoS One"},{"key":"7430_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2020.09.005","volume":"127","author":"M Suski","year":"2020","unstructured":"Suski M, Wi\u015bniewska A, Ku\u015b K, et al. Decrease of the pro-inflammatory M1-like response by inhibition of dipeptidyl peptidases 8\/9 in THP-1 macrophages - quantitative proteomics of the proteome and secretome. Mol Immunol. 2020;127:193\u2013202.","journal-title":"Mol Immunol"},{"key":"7430_CR24","doi-asserted-by":"publisher","first-page":"e001329","DOI":"10.1161\/JAHA.114.001329","volume":"3","author":"A Stachowicz","year":"2014","unstructured":"Stachowicz A, Olszanecki R, Suski M, et al. Mitochondrial Aldehyde Dehydrogenase Activation by Alda-1 Inhibits Atherosclerosis and Attenuates Hepatic Steatosis in Apolipoprotein E-Knockout Mice. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2014;3:e001329.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"7430_CR25","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1021\/ac504689z","volume":"87","author":"JR Wi\u015bniewski","year":"2015","unstructured":"Wi\u015bniewski JR, Gaugaz FZ. Fast and sensitive total protein and Peptide assays for proteomic analysis. Anal Chem. 2015;87:4110\u20136.","journal-title":"Anal Chem"},{"key":"7430_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wi\u015bniewski","year":"2009","unstructured":"Wi\u015bniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359\u201362.","journal-title":"Nat Methods"},{"key":"7430_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1074\/mcp.M114.044305","volume":"14","author":"R Bruderer","year":"2015","unstructured":"Bruderer R, Bernhardt OM, Gandhi T, et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol Cell Proteomics MCP. 2015;14:1400\u201310.","journal-title":"Mol Cell Proteomics MCP"},{"key":"7430_CR28","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1021\/pr070230d","volume":"6","author":"B Zhang","year":"2007","unstructured":"Zhang B, Chambers MC, Tabb DL. Proteomic Parsimony through Bipartite Graph Analysis Improves Accuracy and Transparency. J Proteome Res. 2007;6:3549\u201357.","journal-title":"J Proteome Res"},{"key":"7430_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1467-9868.00346","volume":"64","author":"JD Storey","year":"2002","unstructured":"Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B. Stat Methodol. 2002;64:479\u201398.","journal-title":"Stat Methodol"},{"key":"7430_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nbt.2839","volume":"32","author":"JA Vizca\u00edno","year":"2014","unstructured":"Vizca\u00edno JA, Deutsch EW, Wang R, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32:223\u20136.","journal-title":"Nat Biotechnol"},{"key":"7430_CR31","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1021\/jasms.0c00032","volume":"31","author":"N Sundararaman","year":"2020","unstructured":"Sundararaman N, Go J, Robinson AE, et al. PINE: An Automation Tool to Extract and Visualize Protein-Centric Functional Networks. J Am Soc Mass Spectrom. 2020;31:1410\u201321.","journal-title":"J Am Soc Mass Spectrom"},{"key":"7430_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinforma Oxf Engl. 2009;25:1091\u20133.","journal-title":"Bioinforma Oxf Engl"},{"key":"7430_CR33","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"7430_CR34","doi-asserted-by":"crossref","unstructured":"Crewe C, Zhu Y, Paschoal VA, et al. SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. JCI Insight. 4:e129397.","DOI":"10.1172\/jci.insight.129397"},{"key":"7430_CR35","doi-asserted-by":"publisher","first-page":"30028","DOI":"10.1074\/jbc.274.42.30028","volume":"274","author":"I Shimomura","year":"1999","unstructured":"Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028\u201332.","journal-title":"J Biol Chem"},{"key":"7430_CR36","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1073\/pnas.0603115103","volume":"103","author":"J Mao","year":"2006","unstructured":"Mao J, DeMayo FJ, Li H, et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA. 2006;103:8552\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7430_CR37","first-page":"11816","volume":"34","author":"M Weber","year":"2020","unstructured":"Weber M, Mera P, Casas J, et al. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB J Off Publ Fed Am Soc Exp Biol. 2020;34:11816\u201337.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"7430_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1530\/JOE-16-0447","volume":"232","author":"A Wolf Greenstein","year":"2017","unstructured":"Wolf Greenstein A, Majumdar N, Yang P, et al. Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice. J Endocrinol. 2017;232:107\u201321.","journal-title":"J Endocrinol"},{"key":"7430_CR39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952\u201364.","journal-title":"J Hepatol"},{"key":"7430_CR40","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9\u201319.","journal-title":"Hippokratia"},{"key":"7430_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jobaz.2016.01.001","volume":"77","author":"AM Soliman","year":"2016","unstructured":"Soliman AM. Potential impact of Paracentrotus lividus extract on diabetic rat models induced by high fat diet\/streptozotocin. J Basic Appl Zool. 2016;77:8\u201320.","journal-title":"J Basic Appl Zool"},{"key":"7430_CR42","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bbrc.2017.11.054","volume":"495","author":"M Zhang","year":"2018","unstructured":"Zhang M, Zhao Y, Li Z, et al. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. Biochem Biophys Res Commun. 2018;495:582\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"7430_CR43","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","volume":"9","author":"W Mu","year":"2019","unstructured":"Mu W, Cheng X, Liu Y, et al. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues. Front Pharmacol. 2019;9:1566.","journal-title":"Front Pharmacol"},{"key":"7430_CR44","first-page":"595371","volume":"8","author":"AP Delli Bovi","year":"2021","unstructured":"Delli Bovi AP, Marciano F, Mandato C, et al. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review Front Med. 2021;8:595371.","journal-title":"An Updated Mini Review Front Med"},{"key":"7430_CR45","doi-asserted-by":"publisher","first-page":"E3379","DOI":"10.3390\/nu12113379","volume":"12","author":"A Pani","year":"2020","unstructured":"Pani A, Giossi R, Menichelli D, et al. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients. 2020;12:E3379.","journal-title":"Nutrients."},{"key":"7430_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1172\/JCI8814","volume":"105","author":"IA Leclercq","year":"2000","unstructured":"Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067\u201375.","journal-title":"J Clin Invest"},{"key":"7430_CR47","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1194\/jlr.C120001160","volume":"61","author":"XC Dong","year":"2020","unstructured":"Dong XC. A closer look at the mysterious HSD17B13. J Lipid Res. 2020;61:1361\u20132.","journal-title":"J Lipid Res"},{"key":"7430_CR48","doi-asserted-by":"publisher","first-page":"120438","DOI":"10.1016\/j.lfs.2022.120438","volume":"296","author":"L Zhu","year":"2022","unstructured":"Zhu L, Li B, Chen D, et al. sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes. Life Sci. 2022;296:120438.","journal-title":"Life Sci"},{"key":"7430_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1440-1681.12927","volume":"45","author":"A Stachowicz","year":"2018","unstructured":"Stachowicz A, Olszanecki R, Suski M, et al. Quantitative proteomics reveals decreased expression of major urinary proteins in the liver of apoE\/eNOS-DKO mice. Clin Exp Pharmacol Physiol. 2018;45:711\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"7430_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18:666\u201382.","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07430-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:34:34Z","timestamp":1721792074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07430-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7430"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07430-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"11 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors consented for publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}